Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,685
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
stocks
Market overreacts to earnings miss from moated ASX retailer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,245.00 | 66.30 | -0.71% |
CAC 40 | 7,843.04 | 126.65 | -1.59% |
DAX 40 | 24,273.12 | 89.97 | -0.37% |
Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
FTSE 100 | 9,321.40 | 12.20 | 0.13% |
HKSE | 25,829.91 | 490.77 | 1.94% |
NASDAQ | 21,449.29 | 47.24 | -0.22% |
Nikkei 225 | 42,807.82 | 174.53 | 0.41% |
NZX 50 Index | 13,079.50 | 36.74 | 0.28% |
S&P 500 | 6,439.32 | 27.59 | -0.43% |
S&P/ASX 200 | 8,972.40 | 71.70 | -0.79% |
SSE Composite Index | 3,883.56 | 57.80 | 1.51% |